197 related articles for article (PubMed ID: 20562921)
1. Ral activation promotes melanomagenesis.
Zipfel PA; Brady DC; Kashatus DF; Ancrile BD; Tyler DS; Counter CM
Oncogene; 2010 Aug; 29(34):4859-64. PubMed ID: 20562921
[TBL] [Abstract][Full Text] [Related]
2. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.
Issaq SH; Lim KH; Counter CM
Mol Cancer Res; 2010 Feb; 8(2):223-31. PubMed ID: 20145037
[TBL] [Abstract][Full Text] [Related]
3. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation.
Mishra PJ; Ha L; Rieker J; Sviderskaya EV; Bennett DC; Oberst MD; Kelly K; Merlino G
Oncogene; 2010 Apr; 29(16):2449-56. PubMed ID: 20118982
[TBL] [Abstract][Full Text] [Related]
4. Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.
Kidd AR; Snider JL; Martin TD; Graboski SF; Der CJ; Cox AD
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):205-12. PubMed ID: 20619549
[TBL] [Abstract][Full Text] [Related]
5. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
Vigil D; Martin TD; Williams F; Yeh JJ; Campbell SL; Der CJ
J Biol Chem; 2010 Nov; 285(45):34729-40. PubMed ID: 20801877
[TBL] [Abstract][Full Text] [Related]
6. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
7. Association of activated c-Met with NRAS-mutated human melanomas.
Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
[TBL] [Abstract][Full Text] [Related]
8. Activation of RalA is critical for Ras-induced tumorigenesis of human cells.
Lim KH; Baines AT; Fiordalisi JJ; Shipitsin M; Feig LA; Cox AD; Der CJ; Counter CM
Cancer Cell; 2005 Jun; 7(6):533-45. PubMed ID: 15950903
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.
Yin J; Pollock C; Tracy K; Chock M; Martin P; Oberst M; Kelly K
Mol Cell Biol; 2007 Nov; 27(21):7538-50. PubMed ID: 17709381
[TBL] [Abstract][Full Text] [Related]
11. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE
Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692
[TBL] [Abstract][Full Text] [Related]
12. The RalGEF/Ral pathway: evaluating an intervention opportunity for Ras cancers.
Cooper JM; Bodemann BO; White MA
Enzymes; 2013; 34 Pt. B():137-56. PubMed ID: 25034103
[TBL] [Abstract][Full Text] [Related]
13. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
14. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
16. The RAL signaling network: Cancer and beyond.
Apken LH; Oeckinghaus A
Int Rev Cell Mol Biol; 2021; 361():21-105. PubMed ID: 34074494
[TBL] [Abstract][Full Text] [Related]
17. Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth.
Goi T; Rusanescu G; Urano T; Feig LA
Mol Cell Biol; 1999 Mar; 19(3):1731-41. PubMed ID: 10022860
[TBL] [Abstract][Full Text] [Related]
18. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
19. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
20. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Tecleab A; Zhang X; Sebti SM
J Biol Chem; 2014 Nov; 289(45):31296-309. PubMed ID: 25210032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
